Salarius Pharmaceuticals (NASDAQ: SLRX) announced on Wednesday the initiation of the expansion of its ongoing 1-2 clinical trial of seclidemstat in patients with relapsed and refractory Ewing sarcoma and Ewing related sarcomas.
Seclidemstat is a reversal inhibitor of lysine-specific histone demethylase 1 enzyme that has been shown to play a critical role in the development and progression of certain cancers.
The expansion stage will consist of two treatment arms. The first arm will enrol up to 20 Ewing sarcoma patients and investigate the drug at the recommended Phase 2 dose. The second arm will enrol up to 30 patients with Ewing related sarcomas and study the drug as a single agent therapy.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Salarius expects to report data readouts from the trial towards the end of 2021 and into 2022.
“We believe our clinical program across Ewing and Ewing-related sarcomas allows more patients to receive seclidemstat far earlier in their treatment paradigm, and we believe this could not only increase the clinical benefits of seclidemstat but also provide the best chance to improve survival outcomes,” stated David Arthur president and CEO of Salarius Pharmaceuticals.
The company’s shares are trading 19% higher at $2.30 at the time of writing.
